Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies

(2011) W. P. Yong et al.   ANNALS OF ONCOLOGY

Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue

(2011) V. Novotny-Diermayr et al.   MOLECULAR CANCER THERAPEUTICS

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

(2010) Anne M. Traynor et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Third-Generation Tyrosine Kinase Inhibitors and Beyond

(2010) Alfonso Quintás-Cardama et al.   SEMINARS IN HEMATOLOGY

Mechanism of MK-0457 efficacy against BCR–ABL positive leukemia cells

(2009) Seiichi Okabe et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells

(2009) T.-L. Cha et al.   CLINICAL CANCER RESEARCH

BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?

(2008) John M. Goldman et al.   ACTA HAEMATOLOGICA

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

(2008) Jennifer S. Carew et al.   CANCER LETTERS

Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells

(2008) S. Okabe et al.   CLINICAL CANCER RESEARCH